Kymera Therapeutics Inc (NAS:KYMR)
$ 50.94 1.09 (2.19%) Market Cap: 3.30 Bil Enterprise Value: 2.84 Bil PE Ratio: 0 PB Ratio: 3.69 GF Score: 50/100

Kymera Therapeutics Inc at UBS BioPharma Conference Transcript

Nov 08, 2023 / 03:30PM GMT
Release Date Price: $15.95 (-2.51%)
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

I'm Ellie Merle, one of the biotech analyst here at UBS. Thank you for joining us in a very sunny Miami for the UBS Biopharma Conference. Very happy to have Kymera Therapeutics here with us today for a fireside chat. Joining us from Kymera is Nello Mainolfi, President and Chief Executive Officer.

With that, Nello, thank you so much for joining us.

Questions & Answers

Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director

Thanks, Ellie, for having us.

Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

Of course. And listen, there's a lot of talk around targeted protein degradation. What this could mean as a modality? I think investor feedback recently has been come back in terms of excitement, so relative to 2 years ago. In your view, what do you think people are missing? What have we learned about this modality in the last couple of years from all the clinical data? And what do

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot